DXCM Dexcom Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DXCM

Price (delayed)

$82.97

Market cap

$30.94B

P/E Ratio

32.03

Dividend/share

N/A

EPS

$2.59

Enterprise value

$31.32B

?
Relative Growth: Rel. Growth: 92
Relative Strength: Rel. Strength: 76
Relative Valuation: Rel. Valuation: 43
Relative Profitability: Rel. Profitability: 94

Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. ...

Highlights
The debt has decreased by 47% YoY
The EPS rose by 41% YoY
The stock's price to earnings (P/E) is 63% less than its 5-year quarterly average of 89.6 but 12% more than its last 4 quarters average of 29.1
The company's equity fell by 7% YoY and by 3.3% QoQ
The quick ratio has declined by 2.2% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.dexcom.com
Peers: EW WST BDX TNDM

Key stats

What are the main financial stats of DXCM

DXCM stock price

How has the Dexcom stock price performed over time
Intraday
-2.11%
1 week
5.61%
1 month
-2.8%
1 year
37.3%
YTD
25.01%
QTD
-3.85%

Financial performance

How have Dexcom's revenue and profit performed over time
Revenue
$5.1B
Gross profit
$3.24B
Operating income
$1.22B
Net income
$991M
Gross margin
63.4%
Net margin
19.4%
DXCM's operating income has surged by 57% year-on-year and by 7% since the previous quarter
The operating margin has increased by 40% year-on-year and by 4.8% since the previous quarter
Dexcom's net income has increased by 38% YoY
The net margin has increased by 21% YoY but it has decreased by 3.5% from the previous quarter

Price vs fundamentals

How does DXCM's price correlate with its fundamentals

Growth

What is Dexcom's growth rate over time

Valuation

What is Dexcom stock price valuation
DXCM P/E details
P/E
32.03
P/B
12.35
P/S
6.09
EV/EBIT
24.46
EV/EBITDA
20.14
EV/Sales
6.14
The stock's price to earnings (P/E) is 63% less than its 5-year quarterly average of 89.6 but 12% more than its last 4 quarters average of 29.1
The EPS rose by 41% YoY
DXCM's P/B is 25% above its last 4 quarters average of 10.1 but 23% below its 5-year quarterly average of 16.4
The company's equity fell by 7% YoY and by 3.3% QoQ
The stock's price to sales (P/S) is 42% less than its 5-year quarterly average of 10.7 but 13% more than its last 4 quarters average of 5.5
Dexcom's revenue has increased by 13% YoY and by 2.7% from the previous quarter

Efficiency

How efficient is Dexcom business performance
DXCM's return on invested capital has surged by 54% year-on-year
Dexcom's ROA has increased by 50% YoY and by 4.1% from the previous quarter
The ROE is up by 22% year-on-year
The ROS rose by 16% YoY but it fell by 3.8% QoQ

Dividends

What is DXCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DXCM.

Financial health

How did Dexcom financials performed over time
The company's total assets is 68% higher than its total liabilities
The total liabilities has declined by 22% year-on-year and by 3.4% since the previous quarter
The company's total assets fell by 17% YoY and by 3.4% QoQ
The debt is 47% less than the equity
The debt has decreased by 47% YoY
DXCM's debt to equity is down by 42% YoY but it is up by 3.9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.